Psilocybin-Assisted Therapy vs Transpersonal Psychology

Psilocybin-Assisted Therapy

Tradition

Psychedelic

Founder

Griffiths / Carhart-Harris (2016)

Review status

1 condition assessment available

Official sources

Guidelines and official sources (3)

2 clinical guideline checks · 1 regulatory source check

Read the recommendation and its scope. A source may discuss an approach without recommending it.

• FDA accelerates action on treatments for serious mental illness following Executive Order

  US Food and Drug Administration · 2026-04-24 · Regulatory source · National priority voucher announcement

  Not a treatment recommendation

  FDA announced priority vouchers for psilocybin studies in April 2026. This establishes development activity, not approval or psychotherapy endorsement.

  Scope: Companies studying psilocybin for TRD and MDD

  Source checked 2026-09-06

• Management of Major Depressive Disorder

  VA/DoD · Version 4.0, February 2022; evidence through January 2021 · Clinical guideline · Recommendation 35

  Recommendation against the stated use

  VA/DoD strongly recommends against psilocybin for MDD outside research. This 2022 guideline used evidence through January 2021 and does not review subsequent trials.

  Scope: Psilocybin for MDD outside research settings

  Source checked 2026-09-06

• Clinical Practice Guideline for Management of PTSD and Acute Stress Disorder

  VA/DoD · 2023 · Clinical guideline · Recommendation 17; Table 6, p.37

  Discussed in the source

  VA/DoD finds insufficient evidence for or against psilocybin for PTSD. The statement does not separately establish a psychotherapy-protocol recommendation.

  Scope: Psilocybin pharmacotherapy for adult PTSD; evidence reviewed through May 2022.

  Source checked 2026-09-06

Focus

Experiential + Processing

Format

Individual

Duration

Short (1-3 doses)

Condition-specific assessments

Each conclusion applies to the population and use described. These source-based assessments do not certify the full entry or replace expert clinical review.

Existential & Meaning-Making Concerns

Population and scope: Carefully selected adults with a potentially life-threatening cancer diagnosis and anxiety/mood symptoms, receiving psilocybin with substantial preparation, monitored sessions and follow-up support.

Randomized studies

Griffiths et al. (2016) randomized dose order in a crossover study: 56 people were assigned and 51 completed at least one session. Higher-dose treatment favored several mood and existential outcomes compared with the very-low-dose condition, including life meaning and death acceptance. After crossover at five weeks, the six-month observations lacked an unexposed comparison. The small, predominantly White, highly educated sample, expectancy and masking limits, and intensive support restrict generalization. Transient anxiety, psychological distress and blood-pressure increases occurred. This is a trial-design assessment for that supervised research context, not a guideline endorsement or evidence for all meaning-making concerns or unsupervised use.

Source assessment dated 2026-09-06

• Griffiths et al. 2016, cancer-related distress trial, PDF p. 2
• Griffiths et al. 2016, cancer-related distress trial, PDF p. 7
• Griffiths et al. 2016, cancer-related distress trial, PDF p. 8
• Griffiths et al. 2016, cancer-related distress trial, PDF p. 15

Transpersonal Psychology

Tradition

Existential

Founder

Abraham Maslow / Stanislav Grof (1969)

Review status

Assessment not yet completed

Focus

Experiential + Spiritual

Format

Individual, group

Duration

Variable

Psilocybin-Assisted Therapy

Core mechanism: Psilocybin disrupts default mode network activity; on the standard account the mystical-type experience this can occasion is what produces lasting shifts in perspective and meaning, though whether that experience is necessary to the effect is actively disputed

Ontology: Rigid self-referential processing (depression) or compulsive patterns maintained by entrenched neural networks

Transpersonal Psychology

Core mechanism: Facilitating access to non-ordinary states of consciousness (through breathwork, meditation, psychedelics, or spontaneous experience) enables self-transcendence, integration of biographical/perinatal/transpersonal material, and spiritual development

Ontology: Conventional psychology's map of the psyche is too narrow: human consciousness extends beyond biography into perinatal, archetypal, and transpersonal domains whose constriction produces suffering

Linked only in the Psilocybin-Assisted Therapy entry

Linked only in the Transpersonal Psychology entry

Psilocybin-Assisted Therapy

Philosophical roots: James (mystical experience); Huxley (doors of perception, reducing valve theory); Watts (ego dissolution); Buddhist concepts (non-self, interconnection); Carhart-Harris (entropic brain hypothesis)

Blind spots: Not FDA approved; challenging experiences can be destabilizing; standardization of therapy component still developing

Therapeutic voice: Whatever comes, let it come. Whatever goes, let it go. Trust the process.

Transpersonal Psychology

Philosophical roots: Maslow (hierarchy of needs, peak experiences, self-transcendence); Grof (expanded cartography: perinatal matrices, COEX systems); James (Varieties of Religious Experience); Huxley (perennial philosophy); Jung (collective unconscious); Wilber (integral theory); Buddhist and Hindu contemplative traditions

Blind spots: Minimal empirical base; spiritual bypass risk (using transcendence to avoid mundane psychological work); boundary confusion between psychology and religion; can pathologize or romanticize psychotic experience

Therapeutic voice: I'm not going to call that pathology before I understand it. Tell me what happened afterward. Could you come back? Could you sleep, eat, get yourself to work? What the content was matters less to me than whether you can find your way back from it.